Brink Bites: A Boston Climate Leader and New Oral Cancer Targets
Other research news, stories, and tidbits from around BU, including a potential way to help […]
Office of Research Homepage
Convergent Hire Brings Together Engineering and Biology
Following a national search, Jeroen Eyckmans has been appointed the newest convergent hire in Biomedical […]
How Augmented Reality Could Help Engineers Better Insulate Older Homes
A Boston University-based manufacturing innovation center is developing an AR-guided insulation system to reduce energy […]
Fast Company Names Boston University–Designed Sound Shield a “World Changing Idea”
Technology could make air conditioners, airplanes, and data centers quieter
Would Better Hip Care for Young Female Athletes Prevent Pain and Surgery Later in Life?
Most research into athletes’ hips only studies boys and men. With prevention and better training […]
7,609
publications in 2024
200
+
companies developing and selling products based on BU discoveries
$
574.25
M
total research awards in FY25
AAU
1 of 71 members of the Association of American Universities
You Are Why.
You are why we educate, research, and invest: so we can better serve society, so we can generate life-changing new knowledge, and so we all can succeed.
-
Wilson W. Wong
Professor, Biomedical Engineering -
Ayse Lokmanoglu
Assistant Professor, Emerging Media Studies -
Jeffrey J. Marlow
Assistant Professor, Biology -
Harvey Young
Interim Vice President for the Arts Dean, College of Fine Arts Professor, English, Theatre Arts, American Studies, and African American & Black Diaspora Studies -
Siddharth Mishra-Sharma
Assistant Professor, Computing & Data Sciences -
Tommaso Ranzani
Associate Professor, Mechanical Engineering, Materials Science & Engineering, and Biomedical Engineering -
Pawel Przytycki
Assistant Professor, Computing & Data Sciences -
Dillon Brout
Assistant Professor, Astronomy -
Lee Roberts
Professor, Physics
Boston University-Led Biopharmaceutical Accelerator Boosts New Drugs’ Chances of Success, Study Finds
CARB-X-backed novel to combat antimicrobial resistance are nearly five times more likely to reach clinical development